CCM
Camber Capital Management Portfolio holdings
AUM
$718M
1-Year Est. Return
4.23%
This Fund
S&P 500
1 Year Est. Return
-4.23%
AUM
$1.6B
AUM Growth
-$954M
(-37%)
Holding
38
Top Buys
| 1 | +$73M | |
| 2 | +$38.5M | |
| 3 | +$19.8M | |
| 4 |
Cigna
CI
|
+$16.4M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$3.53M |
Top Sells
| 1 | +$220M | |
| 2 | +$142M | |
| 3 | +$86.6M | |
| 4 |
GSK
GSK
|
+$84.5M |
| 5 |
Ascendis Pharma
ASND
|
+$70.1M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Zimmer Biomet
ZBH
$17B
| $255M | 9.05% |
2,250,000
+645,000
|
|
||
2
Baxter International
BAX
$10.1B
| $197M | 6.99% |
5,750,000
+1,125,000
|
|
||
3
Humana
HUM
$23.7B
| $192M | 6.81% |
725,000
+75,000
|
|
||
4
CVS Health
CVS
$94.5B
| $152M | 5.42% |
2,250,000
-750,000
|
|
||
5
Globus Medical
GMED
$12.1B
| $91.5M | 3.25% |
1,250,000
+25,000
|
|
||
6
PTC Therapeutics
PTCT
$6.14B
| $76.4M | 2.72% |
1,500,000
-1,700,000
|
|
||
|
7
Cigna
CI
$72.5B
| $65.8M | 2.34% |
200,000
+50,000
|
|
||
8
Viatris
VTRS
$15.1B
| $65.3M | 2.32% |
7,500,000
-7,500,000
|
|
||
9
Pfizer
PFE
$148B
| $63.4M | 2.25% |
2,500,000
-2,500,000
|
|
||
10
Qiagen
QGEN
$11.1B
| $56.2M | 2% |
1,400,000
-58,333
|
|
||
|
11
Ascendis Pharma
ASND
$13.7B
| $54.6M | 1.94% |
350,000
-450,000
|
|
||
12
Sarepta Therapeutics
SRPT
$2.22B
| $51.1M | 1.81% |
800,000
-200,000
|
|
||
13
Brookdale Senior Living
BKD
$3.45B
| $39.1M | 1.39% |
6,250,000
-7,685,000
|
|
||
|
14
BioMarin Pharmaceuticals
BMRN
$10.9B
| $35.3M | 1.26% |
500,000
+50,000
|
|
||
|
CON
15
Concentra Group Holdings
CON
$2.77B
| $34.7M | 1.23% |
1,600,000
-1,900,000
|
|
||
16
Evolent Health
EVH
$362M
| $28.4M | 1.01% |
3,000,000
-1,000,000
|
|
||
17
Ionis Pharmaceuticals
IONS
$13.6B
| $21.9M | 0.78% |
725,000
+100,000
|
|
||
18
Myriad Genetics
MYGN
$516M
| $20.8M | 0.74% |
2,350,000
-750,000
|
|
||
|
ZIMV
19
DELISTED
ZimVie
ZIMV
| $20.4M | 0.72% |
1,885,000
-840,000
|
|
||
20
MoonLake Immunotherapeutics
MLTX
$1.15B
| $17.2M | 0.61% |
441,000
|
|
||
21
Denali Therapeutics
DNLI
$3.37B
| $17M | 0.6% |
1,250,000
-1,000,000
|
|
||
22
AnaptysBio
ANAB
$1.32B
| $13.9M | 0.5% |
750,000
-500,000
|
|
||
23
Theravance Biopharma
TBPH
$972M
| $8.93M | 0.32% |
1,000,000
|
|
||
24
10x Genomics
TXG
$2.63B
| $8.73M | 0.31% |
1,000,000
|
|
||
25
Inogen
INGN
$158M
| $6.95M | 0.25% |
975,000
-1,025,000
|
|